This federal contract award, valued at $81,562.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine, with a completion date of December 13, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type, and there is no set-aside designation. Amerisourcebergen Drug Corp is a for-profit organization that is registered in the System for Award Management (SAM.gov) and has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Generated 3/13/25, 10:10 AM